Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease
- 1 January 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 15 (1) , 63-76
- https://doi.org/10.1089/10430340460732463
Abstract
We have previously proposed the CD20 molecule as a novel suicide gene for T lymphocytes in the context of allogeneic bone marrow transplantation, because CD20 can be used both as a selection marker and as a killer gene after exposure to the anti-CD20 therapeutic antibody rituximab. We now report on preclinical studies using this novel system, in which the best transduction protocol, reproducibility, yield, feasibility, and functionality of the transduced T lymphocytes have been investigated with a large donor series. Wild-type human CD20 cDNA was transduced into human T lymphocytes, using a Moloney-derived retroviral vector. Alternative protocols were tested by employing either one or four spinoculations (in which cells are centrifuged in the presence of retroviral vector supernatant) and stimulating T cells with phytohemagglutinin (PHA) or anti-CD3/CD28. One spinoculation alone was sufficient to obtain approximately 30% CD20-positive cells within four experimental days. Four spinoculations significantly increased transduction to 60%. A small difference in transduction efficiency was observed between the two stimulation methods, with PHA being superior to anti-CD3/CD28. Transduced cells could be purified on immunoaffinity columns, with purity reaching 98% and yield being on average 50%. Finally, 86-97% of immunoselected T lymphocytes could be killed in vitro with rituximab and complement. More importantly, the CD20 transgene did not alter the functionality of T lymphocytes with respect to allogeneic recognition and cytotoxic response, anti-Epstein-Barr virus cytotoxic response, antigenic response to tetanus toxoid antigen, interleukin 2 (IL-2), IL-4, and interferon γ production; chemotaxis in the presence of stromal cell-derived factor 1, phenotype for several activation markers including HLA-DR, CD25, CD69, and CD95, and T cell repertoire.Keywords
This publication has 77 references indexed in Scilit:
- New concepts about graft-versus-host and graft-versus-leukaemia-reactions. A summary of the 5th International Symposium held in Munich, 21 and 22 March 2002Bone Marrow Transplantation, 2002
- Evolution of bone marrow transplantation – the original immunotherapyTrends in Immunology, 2001
- Retrovirus-Mediated Gene Transfer in Primary T Lymphocytes: Influence of the Transduction/Selection Process and ofex VivoExpansion on the T Cell Receptor β Chain Hypervariable Region RepertoireHuman Gene Therapy, 2000
- Donor lymphocyte infusionsCurrent Opinion in Hematology, 1999
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirementsGene Therapy, 1999
- Would suicide gene therapy solve the ‘T-cell dilemma’ of allogeneic bone marrow transplantation?Immunology Today, 1999
- Green Fluorescent Protein as a Selectable Marker of Fibronectin-Facilitated Retroviral Gene Transfer in Primary Human T LymphocytesHuman Gene Therapy, 1999
- Assessment of T-Cell receptor β-chain diversity by heteroduplex analysisHuman Immunology, 1996
- Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytesCytometry, 1993